Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study

BMC Gastroenterology

Lei Wan⁵  Wen-Ling Liao¹  Wei-Yong Lin¹  Fuu-Jen Tsai⁶  Yun-Ping Lim²  Ter-Hsin Chen³  Cheng-Yuan Peng⁴ 

[1] Graduate Institute of Integrated Medicine, China Medical University, 40402 Taichung, Taiwan;Department of Pharmacy, College of Pharmacy, China Medical University, 40402 Taichung, Taiwan;Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan;Department of Internal Medicine, China Medical University Hospital, 40402 Taichung, Taiwan;Department of Biotechnology, Asia University, 41354 Taichung, Taiwan;School of Chinese Medicine, China Medical University, No. 91, Hsueh-Shih Road, 40402 Taichung, Taiwan

关键词: Interleukin-28B;    Mannose receptor C;    Sustained virological response;    Standard of care treatment;    Hepatitis C virus;   

Others  :  855092
DOI  :  10.1186/1471-230X-14-113

 received in 2013-04-10, accepted in 2014-06-03,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to evaluate whether polymorphisms of the mannose receptor C type 1 (MRC-1) and interleukin 28B (IL-28B) genes are associated with the treatment outcome of patients infected with hepatitis C virus genotypes 1 and 2 (HCV-1 and HCV-2, respectively) who are treated with peginterferon plus ribavirin (PEG-IFNα-RBV).

Methods

We analyzed the association of the patients’ sustained viral responses (SVRs) to PEG-IFNα-RBV therapy with 2 single nucleotide polymorphisms (SNPs) in MRC-1 and 3 SNPs in IL-28B. We selected patients infected with either HCV-1 (n = 265) or HCV-2 (n = 195) with or without SVR.

Results

Among the MRC-1 SNPs, rs691005 was found to be associated with SVR in HCV-1-infected patients (P < 0.0001). The IL-28B rs8099917 SNP was found to be associated with SVR in HCV-1- and HCV-2-infected patients (HCV-1, P < 0.0001; HCV-2, P = 0.002), while IL-28B rs955155 and rs10853728 SNPs were found to be associated with SVR in HCV-1-infected patients (P = 0.003) and HCV-2-infected patients (P = 0.02), respectively. We also identified an interaction between MRC-1 rs691005 and IL-28B rs8099917 (P = 0.001). The C-T haplotype was shown to have a positive effect on SVR in HCV-1-infected patients (OR = 1.77, 95% CI = 1.2, 2.62), whereas the T-G haplotype was shown to have a negative effect on SVR in HCV-1-infected patients (OR = 0.28, 95% CI = 0.14, 0.58).

Conclusions

These results suggest that SNPs of IL-28B and MRC-1 can be used as genetic markers for predicting the outcome of PEG-IFNα-RBV treatment of HCV infections.

【 授权许可】

   
2014 Peng et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Poordad F, Dieterich D: Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012, 19(7):449-464.
• [2]Gao B, Hong F, Radaeva S: Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004, 39(4):880-890.
• [3]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
• [4]Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL: Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53(1):7-13.
• [5]Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS: IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6(3):e18322.
• [6]Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB, Pharmacogenetics and Hepatitis C Meeting Participants: Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53(1):336-345.
• [7]Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-1345. 1345 e1331-1337
• [8]Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR: Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther 2012, 36(2):91-103.
• [9]Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z: Prediction of response to pegylated-interferon-alpha and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 2012, 9:123.
• [10]Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104.
• [11]Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M: Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J 2012, 9(1):126.
• [12]Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM: Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55(3):666-675.
• [13]Meyer K, Basu A, Ray R: Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000, 276(1):214-226.
• [14]Gummuluru S, Rogel M, Stamatatos L, Emerman M: Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J Virol 2003, 77(23):12865-12874.
• [15]Cambi A, de Lange F, van Maarseveen NM, Nijhuis M, Joosten B, van Dijk EM, de Bakker BI, Fransen JA, Bovee-Geurts PH, van Leeuwen FN, Van Hulst NF, Figdor CG: Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol 2004, 164(1):145-155.
• [16]Cambi A, Gijzen K, de Vries JM, Torensma R, Joosten B, Adema GJ, Netea MG, Kullberg BJ, Romani L, Figdor CG: The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol 2003, 33(2):532-538.
• [17]Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM: The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009, 393(1):84-90.
• [18]Famulski KS, Sis B, Billesberger L, Halloran PF: Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant 2008, 8(3):547-556.
• [19]Hsu SC, Chen CH, Tsai SH, Kawasaki H, Hung CH, Chu YT, Chang HW, Zhou Y, Fu J, Plunkett B, Su SN, Vieths S, Lee RT, Lee YC, Huang SK: Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells. J Biol Chem 2010, 285(11):7903-7910.
• [20]Hattori T, Konno S, Takahashi A, Isada A, Shimizu K, Taniguchi N, Gao P, Yamaguchi E, Hizawa N, Huang SK, Nishimura M: Genetic variants in mannose receptor gene (MRC1) confer susceptibility to increased risk of sarcoidosis. BMC Med Genet 2010, 11:151.
• [21]Wang D, Feng JQ, Li YY, Zhang DF, Li XA, Li QW, Yao YG: Genetic variants of the MRC1 gene and the IFNG gene are associated with leprosy in Han Chinese from Southwest China. Hum Genet 2012, 131(7):1251-1260.
• [22]Alter A, de Leseleuc L, Van Thuc N, Thai VH, Huong NT, Ba NN, Cardoso CC, Grant AV, Abel L, Moraes MO, Alcaïs A, Schurr E: Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 2010, 127(3):337-348.
• [23]Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73(5):1162-1169.
• [24]Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68(4):978-989.
• [25]Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G: Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001, 120(2):512-524.
• [26]Barnes E, Salio M, Cerundolo V, Francesco L, Pardoll D, Klenerman P, Cox A: Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat 2008, 15(3):219-228.
• [27]Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF: Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005, 105(9):3605-3614.
• [28]Rana D, Chawla YK, Duseja A, Dhiman R, Arora SK: Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int 2012, 32(7):1128-1137.
• [29]Kanazawa N: Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen-presenting cells. J Dermatol Sci 2007, 45(2):77-86.
• [30]Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R: C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002, 76(13):6841-6844.
• [31]Kwan WH, Navarro-Sanchez E, Dumortier H, Decossas M, Vachon H, dos Santos FB, Fridman HW, Rey FA, Harris E, Despres P, Mueller CG: Dermal-type macrophages expressing CD209/DC-SIGN show inherent resistance to dengue virus growth. PLoS Negl Trop Dis 2008, 2(10):e311.
• [32]Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, Altmeyer R: C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 2004, 279(31):32035-32045.
• [33]Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K: Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2011, 83(6):981-988.